keyword
MENU ▼
Read by QxMD icon Read
search

New treatment in HCV

keyword
https://www.readbyqxmd.com/read/28927831/-beyond-the-willing-the-waiting-the-role-of-peer-based-approaches-in-hepatitis-c-diagnosis-treatment
#1
Charles Henderson, Annie Madden, Jenny Kelsall
This commentary seeks to examine the role, value and importance of peer-based programmatic approaches for ensuring the effective roll-out of the new hepatitis C (HCV) treatments among those most affected - that is, people who inject drugs (PWID). The authors examine recent approaches to HCV treatment in Australia including the provision of universal access to the new DAA regimens regardless of acquisition, genotype or severity of disease. These approaches are contextualised within wider global strategies to support HCV elimination as a public health threat by 2030 (WHO, 2016)...
September 15, 2017: International Journal on Drug Policy
https://www.readbyqxmd.com/read/28926561/mechanisms-of-accelerated-liver-fibrosis-in-hiv-hcv-coinfection
#2
Theofilos Chrysanthidis, Georgia Loli, Simeon Metallidis, Georgios Germanidis
Although there is evidence that HCV progresses rapidly in HIV/HCV coinfected patients in comparison with HCV monoinfected, the HIV-, HCV- and host/genetic-related factors, as well as the exact mechanisms implicated in this process are not fully elucidated. Furthermore, cure of HCV in those coinfected seems possible with the new antiviral drugs, but high cost as well as insufficient identification, linkage with care and treatment hamper the achievement of this goal. Research on the subject, could reveal an important prognostic marker for the effectiveness of persuasion of patients with HIV/HCV coinfection with a predicted accelerated fibrosis course, in order to facilitate and prioritize, not in terms of guidelines but in the real life situation, their treatment with a medically just framework...
September 19, 2017: AIDS Reviews
https://www.readbyqxmd.com/read/28925068/when-and-how-can-nephrologists-treat-hepatitis-c-virus-infection-in-dialysis-patients
#3
REVIEW
Maya I Davis, Donald F Chute, Raymond T Chung, Meghan E Sise
Hepatitis C virus (HCV) infection, a major cause of end-stage liver disease, is a common comorbidity in patients on dialysis and causes increased morbidity and mortality. Historically HCV has been extremely difficult to cure with interferon and ribavirin-based therapies, which are also associated with significant side effects, and few dialysis patients ever received HCV treatment. However, in the last 4 years, interferon-free direct-acting antiviral therapies have been approved, and several combinations have been studied in dialysis patients...
September 18, 2017: Seminars in Dialysis
https://www.readbyqxmd.com/read/28924449/outcomes-after-sofosbuvir-containing-regimens-for-hepatitis-c-virus-in-patients-with-decompensated-cirrhosis-a-real-world-study
#4
Fanpu Ji, Wenjun Wang, Shuangsuo Dang, Shengbang Wang, Burong Li, Dan Bai, Wenxue Zhao, Hong Deng, Changyin Tian, Zongfang Li
BACKGROUND: Direct-acting antivirals have been used for decompensated cirrhotic patients with hepatitis C virus (HCV) infection. However, the benefits in Chinese patients with decompensated cirrhosis are unclear. METHODS: Thirty patients with HCV infection and decompensated cirrhosis were administered sofosbuvir-containing regimens at our hospital between April and December 2015. The efficacy and safety of the treatments was determined by sustained virological response at week 12 (SVR 12), change of liver function and adverse events...
2017: Infectious Agents and Cancer
https://www.readbyqxmd.com/read/28922704/direct-acting-antivirals-for-chronic-hepatitis-c
#5
REVIEW
Janus C Jakobsen, Emil Eik Nielsen, Joshua Feinberg, Kiran Kumar Katakam, Kristina Fobian, Goran Hauser, Goran Poropat, Snezana Djurisic, Karl Heinz Weiss, Milica Bjelakovic, Goran Bjelakovic, Sarah Louise Klingenberg, Jian Ping Liu, Dimitrinka Nikolova, Ronald L Koretz, Christian Gluud
BACKGROUND: Millions of people worldwide suffer from hepatitis C, which can lead to severe liver disease, liver cancer, and death. Direct-acting antivirals (DAAs), e.g. sofosbuvir, are relatively new and expensive interventions for chronic hepatitis C, and preliminary results suggest that DAAs may eradicate hepatitis C virus (HCV) from the blood (sustained virological response). Sustained virological response (SVR) is used by investigators and regulatory agencies as a surrogate outcome for morbidity and mortality, based solely on observational evidence...
September 18, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28922445/position-paper-on-treatment-of-hepatitis-c-in-romania-2017-part-two
#6
Liana Gheorghe, Ioan Sporea, Speranta Iacob, Roxana Sirli, Anca Trifan, Mircea Diculescu, Carol Stanciu, Oliviu Pascu, Monica Acalovschi, Ciprian Brisc, Cristina Cijevschi, Cristian Gheorghe, Zeno Spârchez, Ion Rogoveanu, Daniela Dobru, Dan L Dumitrascu
BACKGROUND AND AIMS: Hepatitis C virus (HCV) infection is a common condition with endemic prevalence in some areas of the world. In Romania, the mean prevalence is about 3%. New treatments have become available on the market in recent years and new drugs are in the pipeline. A re-evaluation of HCV therapy was considered mandatory. The Romanian Society of Gastroenterology and Hepatology undertook this task for the practitioners of this country. METHODOLOGY: A group of recognized experts was created who screened the available literature and the major available guidelines...
September 2017: Journal of Gastrointestinal and Liver Diseases: JGLD
https://www.readbyqxmd.com/read/28904942/a-simple-but-accurate-method-for-evaluating-drug-resistance-in-infectious-hcvcc-system
#7
Jian-Rui Li, Wen-Jing Li, Jun-Jun Cheng, Meng-Hao Huang, Zhou-Yi Wu, Chen-Chen Jiang, Hu Li, Jin-Hua Chen, Xiao-Qin Lv, Biao Dong, Jian-Dong Jiang, Zong-Gen Peng
Use of direct-acting antivirals sometimes causes viral drug resistance, resulting in inefficiency in treated patients in real-world practice. Therefore, how to rapidly and accurately evaluate drug resistance is an urgent problem to be solved for rational use and development of antivirals in the future. Here, we aim to develop a new method by which we can evaluate easily but effectively whether a drug will still be efficient in the future treatment in infectious hepatitis C virus cell culture system. HCV-infected Huh7...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28901852/recent-advancement-of-direct-acting-antiviral-agents-daas-in-hepatitis-c-therapy
#8
Debasis Das, Mayank Pandya
Hepatitis C virus (HCV) infection is a major health burden worldwide. Approximately, 170-200 million individuals are chronically infected worldwide and a quarter of these patients are at increased risk of developing liver cirrhosis, hepatocellular carcinoma and even liver failure. A complete eradication of the virus is one of the most important treatment goal for antiviral research. In 2011, the first-generation protease inhibitors boceprevir (BOC) telaprevir (TVR) have been approved by FDA as the direct-acting antiviral agents...
September 12, 2017: Mini Reviews in Medicinal Chemistry
https://www.readbyqxmd.com/read/28891344/when-the-cure-is-the-risk-understanding-how-substance-use-affects-hiv-and-hcv-in-a-layered-risk-environment-in-san-juan-puerto-rico
#9
Diana Hernández, Pedro C Castellón, Yohansa Fernández, Francisco A Torres-Cardona, Carrigan Parish, Danielle Gorshein, Jose Vargas Vidot, Sandra Miranda de Leon, Allan Rodriguez, Jorge Santana Bagur, Daniel J Feaster, Bruce R Schackman, Lisa R Metsch
BACKGROUND: Substance use, particularly injection drug use, continues to fuel the HIV/HCV (hepatitis C virus) epidemics in San Juan, Puerto Rico (PR). AIM: This article examines individual and sociostructural factors that affect HIV/HCV risk among people who use drugs (PWUD) living with or at risk for HIV/HCV in San Juan, PR. Findings were used to inform a community-level intervention to enhance HIV care access and retention for this population. METHOD: A rapid ethnographic assessment in collaboration with a community-based organization was conducted...
September 1, 2017: Health Education & Behavior: the Official Publication of the Society for Public Health Education
https://www.readbyqxmd.com/read/28882581/premature-ovarian-senescence-and-high-miscarriage-rate-impair-fertility-in-women-with-hepatitis-c-virus-infection
#10
Aimilia Karampatou, Xue Han, Loreta A Kondili, Gloria Taliani, Alessia Ciancio, Filomena Morisco, Rosina Maria Critelli, Enrica Baraldi, Veronica Bernabucci, Giulia Troshina, Maria Guarino, Simonetta Tagliavini, Federica D'Ambrosio, Laura Bristot, Laura Turco, Stefano Rosato, Stefano Vella, Tommaso Trenti, Isabella Neri, Antonio La Marca, Shivaji Manthena, Andrea S Goldstein, Savino Bruno, Yanjun Bao, Yuri Sanchez Gonzalez, Erica Villa
BACKGROUND AND AIMS: Premenopausal Hepatitis C Virus positive (HCV+) women have failing ovarian function.We thus investigated reproductive history,risk of infertility and pregnancy outcomes in HCV+ women of childbearing age. METHODS: Three different groups were studied:1) Clinical cohort:100 HCV+ women with chronic liver disease (CLD), age matched with 50 HBV+ women with CLD and with 100 healthy women consecutively observed in 3 Italian Gastroenterology Units;2) 1998 HCV+ women enrolled in the Italian Platform for the Study of Viral Hepatitis Therapies (PITER);3) 6...
September 4, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28872283/impact-of-selected-predictive-factors-on-sustained-virologic-response-in-hcv-genotype-4-infected-patients-treated-with-pegylated-interferon-alpha-and-ribavirin
#11
Dorota Kozielewicz, Anna Grabińska, Grzegorz Madej, Magdalena Wietlicka-Piszcz
BACKGROUND: Dual therapy (PegIFN and ribavirin) (DT) had been the standard of care in patients infected with HCV genotype 4 (HCV-4) until 2014. Thereafter, new treatment options were available including IFNbased and other IFN-free regimens. Objectives: The aim was to assess the efficacy (SVR24) of DT and a selection of predictive factors of SVR in HCV-4 infected patients. METHODS: 112 patients (62 men) of median age 23 years were treated with DT for 48/72 weeks (107/5)...
2017: Przegla̧d Epidemiologiczny
https://www.readbyqxmd.com/read/28865357/check-point-inhibitors-as-therapies-for-infectious-diseases
#12
REVIEW
Maureen A Cox, Robert Nechanitzky, Tak W Mak
The recent successes of immune check point targeting therapies in treating cancer patients has driven a resurgence of interest in targeting these pathways in chronically infected patients. While still in early stages, basic and clinical data suggest that blockade of CTLA-4 and PD-1 can be beneficial in the treatment of chronic HIV, HBV, and HCV infection, as well as other chronic maladies. Furthermore, novel inhibitory receptors such as Tim-3, LAG-3, and TIGIT are the potential next wave of check points that can be manipulated for the treatment of chronic infection...
August 30, 2017: Current Opinion in Immunology
https://www.readbyqxmd.com/read/28863156/molecular-characterization-and-epidemic-history-of-hepatitis-c-virus-using-core-sequences-of-isolates-from-central-province-saudi-arabia
#13
Medhat K Shier, James C Iles, Mohammad S El-Wetidy, Hebatallah H Ali, Mohammad M Al Qattan
The source of HCV transmission in Saudi Arabia is unknown. This study aimed to determine HCV genotypes in a representative sample of chronically infected patients in Saudi Arabia. All HCV isolates were genotyped and subtyped by sequencing of the HCV core region and 54 new HCV isolates were identified. Three sets of primers targeting the core region were used for both amplification and sequencing of all isolates resulting in a 326 bp fragment. Most HCV isolates were genotype 4 (85%), whereas only a few isolates were recognized as genotype 1 (15%)...
2017: PloS One
https://www.readbyqxmd.com/read/28859220/projections-of-primary-liver-cancer-to-2030-in-30-countries-worldwide
#14
Patricia C Valery, Mathieu Laversanne, Paul J Clark, Jessica L Petrick, Katherine A McGlynn, Freddie Bray
Primary liver cancer (PLC) is the sixth most common cancer worldwide and the second most common cause of cancer death. Future predictions can inform health planners and raise awareness of the need for cancer control action. We predicted the future burden of PLC in 30 countries around 2030. Incident cases of PLC (ICD-10 C22) were obtained from 30 countries for 1993-2007. We projected new PLC cases through to 2030 using age-period-cohort models (NORDPRED). Age-standardized incidence rates per 100,000 person-years were calculated by country and sex...
August 31, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28851531/impact-of-old-schistosomiasis-infection-on-the-use-of-transient-elastography-fibroscan-for-staging-of-fibrosis-in-chronic-hcv-patients
#15
Iman Ramzy, Aisha Elsharkawy, Rabab Fouad, Hanan Abdel Hafez, Maissa El Raziky, Wafaa El Akel, Mohammad El-Sayed, Hany Khattab, Mohamed Shehata, Marwa Elsharkawy, Amr Radwan, Gamal Esmat
BACKGROUND AND AIM: In tropical regions, Hepatitis C virus (HCV) - Schistosomiasis coinfection remains one of the health problems. With the new era of HCV treatment and the variety of methods of assessment of liver fibrosis so we aimed to evaluate the effectiveness of FibroScan for staging hepatic fibrosis in HCV-Schistosomiasis coinfected patients. METHODOLOGY: Three groups of patients were enrolled. Group 1: chronic HCV with out antischistosomal antibody (122 patients), Group 2: chronic HCV with positive antischistosomal antibodies and without periportal tract thickening (122 patients), Group 3: chronic HCV with positive antischistosomal antibodies and ultrasonographic picture of periportal tract thickening (108 patients)...
August 26, 2017: Acta Tropica
https://www.readbyqxmd.com/read/28844170/non-healthcare-costs-of-hepatitis-c-a-systematic-review
#16
Natàlia Pascual-Argente, Jaume Puig-Junoy, Anna Llagostera-Punzano
There is an increasing interest in the indirect (or non-healthcare) costs of hepatitis C virus (HCV). Areas covered: Systematic review of original studies on the non-healthcare costs of HCV published in English or Spanish between January 2000 and March 2017. 19 studies addressing non-healthcare cost of HCV were included in the analysis. All studies but one contain treatments with monotherapy or dual therapy prior to the recent introduction of innovative and highly effective direct acting antivirals (DAAs). Five studies estimate the incremental non-healthcare cost of HCV with a control group, which is regarded as high-quality methodology...
September 8, 2017: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28838464/clearance-of-hepatitis-c-virus-prior-to-lung-transplantation-a-case-report
#17
A E Shafii, D D Harris, M Baz
Hepatitis C virus (HCV) continues to be considered a relative contraindication to lung transplantation due to concerns of progression of liver disease with the introduction of immunosuppression. Since the recent introduction of effective antiviral therapy for HCV, new approaches in the management of the HCV-positive recipient are being utilized in liver transplantation to clear HCV pre- and post-transplant. Herein, we report use of ledipasvir/sofosbuvir for HCV clearance prior to lung transplantation in a patient with usual interstitial pneumonia...
September 2017: Transplantation Proceedings
https://www.readbyqxmd.com/read/28835817/do-we-really-need-more-evidence-to-use-hepatitis-c-positive-donor-kidney-more-liberally
#18
Kiran Joglekar, James D Eason, Miklos Z Molnar
The number of patients listed active for kidney transplantation has continued to rise over the last 10 years, leading to significantly increased wait-list time for patients awaiting kidney transplantation in the USA. This increased demand has led to a supply-demand mismatch and should prompt clinicians to seek timely solutions to improve access to available organs. Hepatitis C virus positive [HCV(+)] kidneys continue to be discarded without clear evidence that they lead to poor outcomes in the current era of highly efficacious HCV treatment with direct-acting antiviral agents (DAAs)...
August 2017: Clinical Kidney Journal
https://www.readbyqxmd.com/read/28835776/rapid-liver-and-spleen-stiffness-improvement-in-compensated-advanced-chronic-liver-disease-patients-treated-with-oral-antivirals
#19
Mònica Pons, Begoña Santos, Macarena Simón-Talero, Meritxell Ventura-Cots, Mar Riveiro-Barciela, Rafael Esteban, Salvador Augustin, Joan Genescà
BACKGROUND: We aimed to investigate the early changes in liver and spleen stiffness measurement (LSM, SSM) in hepatitis C virus (HCV) patients with compensated advanced chronic liver disease (cACLD) treated with new antivirals (DAA) to elucidate factors determining the initial change in stiffness and its implications for the long-term follow up of HCV-cured patients. METHODS: A total of 41 patients with cACLD who started DAA therapy underwent LSM and SSM at baseline, week 4, end of treatment (EOT), 24 and 48 weeks of follow up using transient elastography...
August 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28828170/hcv-infected-renal-transplant-recipients-our-experience-before-the-availability-of-new-antiviral-drugs
#20
A R Fernandes, I J Laranjinha, R Birne, P Matias, C Jorge, T Adragão, M Bruges, A Weigert, D Machado
BACKGROUND: Natural history of HCV-infected renal transplant recipients is about to change with the invention of new drugs available for the treatment of HCV. OBJECTIVE: To analyze the evolution of renal transplant recipients infected with HCV in 30 years of activity of a Renal Transplantation Unit. METHODS: We studied 1334 patients who underwent renal transplantation between 1985 and 2015. RESULTS: 189 (14.2%) of these 1334 were found HCV seropositive...
2017: International Journal of Organ Transplantation Medicine
keyword
keyword
36135
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"